ClinicalTrials.gg
CompletedNCT03504852Updated Oct 11, 2021Results posted

Efficacy and Safety of 2 Secukinumab Regimens in 90kg or More Weight Group With Moderate/Severe Chronic Plaque Psoriasis

A Phase 3 interventional study of secukinumab 150 mg in Moderate to Severe Chronic Plaque-type Psoriasis, sponsored by Novartis Pharmaceuticals. Completed at 67 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-11.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
331
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 54 studies testing secukinumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. secukinumab · Psoriasis.

Enrollment
10th of 54
331 · median 124
Started
2018
with 1 other
Phase 3
24 of 54
none open now
Registered
40th of 54
by date
Lead sponsor
37 of 54
Novartis Pharmaceuticals

Among the 54 studies testing secukinumab in Psoriasis, this one is the 10th largest by enrollment, is one of 2 that started in 2018, is one of 24 in phase 3, and was the 40th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 54 studies testing secukinumab in Psoriasis are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About secukinumab

secukinumab: first FDA approval 2015 (COSENTYX), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies testing secukinumab in Psoriasis, or all of them as a file.
02

Study summary

The purpose of this study is to assess secukinumab high dose (every 2 weeks) vs standard dose (every 4 weeks) in heavy body weight subjects with moderate to severe plaque psoriasis.

Read the detailed description

A 52-week multicenter, randomized, double-blind, parallel-group trial in 331 subjects with moderate to severe chronic plaque-type psoriasis of body weight 90 kg or higher at time of randomization.

This study consisted of 4 periods: screening (up to 4 weeks), treatment Period 1 (16 weeks), treatment Period 2 (36 weeks), and post-treatment follow-up (8 weeks).

Subjects were randomized using a 1:1 ratio to the following groups: Secukinumab 300 mg every 2 weeks; Secukinumab 300 mg every 4 weeks.

In addition, subjects from the 300 mg every 4 weeks group who did not achieve Psoriasis Area Severity Index (PASI) 90 response at Week 16 were reassigned using a 1:1 ratio to either remain on secukinumab 300 mg every 4 weeks or receive secukinumab 300 mg every 2 weeks starting at Week 16, until the end of treatment.

03

Conditions studied

  • Moderate to Severe Chronic Plaque-type Psoriasis

Keywords

  • psoriasis
  • secukinumab
  • immune-mediated systemic disease
  • papules
  • plaques
  • itching
  • weight
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Written must have been obtained before any assessment was performed. Where relevant, a legal representative will also have signed the informed study consent according to local laws and regulations.
  • Subjects must have been able to understand and communicate with the investigator and comply with the requirements of the study.
  • Men or women at least 18 years of age at time of screening.
  • Body weight of ≥ 90 kg at the time of randomization.
  • Chronic plaque-type psoriasis present for at least 6 months and diagnosed before randomization.
  • Moderate to severe psoriasis as defined at randomization by:

    • Psoriasis Area and Severity Index (PASI) score of 12 or greater, and
    • Investigator's Global Assessment (IGA) mod 2011 score of 3 or greater (based on a static scale of 0 - 4), and
    • Body Surface Area (BSA) affected by plaque-type psoriasis of 10% or greater.
  • Candidate for systemic therapy. This is defined as a subject having moderate to severe chronic plaque-type psoriasis that is inadequately controlled by:

    • topical treatment and/or,
    • phototherapy and/or,
    • previous systemic therapy.

Key Exclusion Criteria:

  • Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and guttate psoriasis) at screening or Randomization.
  • Ongoing use of prohibited treatments. detailed in the protocol have to be adhered to. Subjects not willing to limit ultraviolet (UV) light exposure (e.g., sunbathing and / or the use of tanning devices) during the course of the study will be considered not eligible for this study since UV light exposure is prohibited. Note: administration of 6 weeks prior to Randomization or during the study period is also prohibited.
  • Previous exposure to secukinumab (AIN457) or any other biologic drug directly targeting Interleukin-17 (IL-17) or the IL-17 receptor.
  • Use of other drugs at the time of enrollment, or within 5 half-lives of enrollment, or within 4 weeks until the expected pharmacodynamic effect has returned to baseline, whichever is longer; or longer if required by local regulations.
  • Pregnant or nursing (lactating) women
  • History of lymphoproliferative disease or any known or history of malignancy of any organ system treated or untreated within the past 5 years, regardless of whether there is evidence of local recurrence or (except for skin Bowen's disease, or basal cell carcinoma or actinic keratoses that have been treated with no evidence of recurrence in the past 12 weeks; carcinoma in situ of the cervix or non-invasive malignant colon polyps that have been removed).
  • History of to any of the study drug constituents.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
331 participants (actual)

Study arms

  • Experimental
    Secukinumab 300 mg every 2 weeks (Q2W)

    2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter every 2 weeks. Subjects remained on secukinumab 300 mg every 2 weeks until the end of treatment.

    Drug: secukinumab 150 mg

  • Active comparator
    Secukinumab 300 mg every 4 weeks (Q4W)

    2 injections of secukinumab 150 mg once weekly up to week 4 and thereafter Q4W. Includes both subjects randomized to remain on Q4W the entire treatment period, and subjects that were Psoriasis Area and Severity Index (PASI) 90 responders at Week 16 from the secukinumab 300 mg Q4W possible up-titrate group.

    Drug: secukinumab 150 mg

  • Active comparator
    Secukinumab 300 mg every 4 weeks non-responders up-titration (Q4W NR up)

    2 injections of secukinumab 150 mg once weekly up to week 4, then Q4W up to Week 16 and thereafter Q2W. Includes Psoriasis Area and Severity Index (PASI) 90 non-responders (NR) at Week 16 from the secukinumab 300 mg Q4W possible up-titrate group (subjects randomized to switch to Q2W if PASI 90 non-responder at Week 16).

    Drug: secukinumab 150 mg

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects Who Achieve 90% or Greater Reduction in Psoriasis Area and Severity Index (PASI) Score - Week 16 (Full Analysis Set)

    A subject was considered as a PASI 90 responder if s/he achieved a reduction of 90% or more of the PASI score, compared to baseline, at a given time point.The head, trunk, upper limbs and lower limbs were assessed separately for erythema, thickening, and scaling. PASI scores can range from a lower value of 0, corresponding to no signs of psoriasis, up to a theoretic maximum of 72.0, i.e., higher scores represent more severity.

    Time frame: 16 weeks

Secondary outcomes

  1. Percentage of Subjects Who Achieve Investigator Global Assessment (IGA Modified 2011) Score of 0 or 1 - Week 16 (Full Analysis Set)

    IGA mod 2011 was conducted for overall psoriatic disease. The IGA modified 2011 used in this study was static, i.e., it referred exclusively to the subject's disease state at the time of the assessments, and did not attempt a comparison with any of the subject's previous disease states, whether at baseline or at a previous visit. The scale has 0 (clear) as min and 4 (severe) as max, i.e., a higher score indicates more severity.

    Time frame: 16 weeks

  2. Absolute and Relative Frequencies for Deaths, Other Serious or Clinically Significant Adverse Events or Related Discontinuations - Entire Study Period (Safety Set)

    An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject after providing written informed consent for participation in the study until the end of study visit. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.

    Time frame: Adverse events were reported from first dose of study treatment until end of study treatment plus 8 weeks post treatment, up to a maximum timeframe of 470 days.

07

Results

Posted Jun 7, 2021

Participant flow

Participant flow — Overall Study
MilestoneSecukinumab 300 mg Every 2 Weeks (Q2W)Secukinumab 300 mg Every 4 Weeks (Q4W) (Safety)Secukinumab 300 mg Every 4 Weeks Non-responders Up-titration (Q4W NR up)
Started16513531
Completed14811728
Not completed17183
Withdrew: Withdrawal of informed consent210
Withdrew: Withdrawal by subject551
Withdrew: Lost to follow-up410
Withdrew: New therapy for study indication100
Withdrew: Lack of efficacy120
Withdrew: Death010
Withdrew: Adverse event482

Outcome measures

PrimaryPercentage of Subjects Who Achieve 90% or Greater Reduction in Psoriasis Area and Severity Index (PASI) Score - Week 16 (Full Analysis Set)

A subject was considered as a PASI 90 responder if s/he achieved a reduction of 90% or more of the PASI score, compared to baseline, at a given time point.The head, trunk, upper limbs and lower limbs were assessed separately for erythema, thickening, and scaling. PASI scores can range from a lower value of 0, corresponding to no signs of psoriasis, up to a theoretic maximum of 72.0, i.e., higher scores represent more severity.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Percentage of Subjects Who Achieve 90% or Greater Reduction in Psoriasis Area and Severity Index (PASI) Score - Week 16 (Full Analysis Set)
ParticipantsSecukinumab 300 mg Every 2 Weeks (Q2W)Secukinumab 300 mg Every 4 Weeks (Q4W) (up to Week 16 Pre-dose)
Percentage of Subjects Who Achieve 90% or Greater Reduction in Psoriasis Area and Severity Index (PASI) Score - Week 16 (Full Analysis Set)12192
Statistical analysis
  • Secukinumab 300 mg Every 2 Weeks (Q2W) vs Secukinumab 300 mg Every 4 Weeks (Q4W) (up to Week 16 Pre-dose) · Regression, Logistic · p = 0.0003 (One-sided p-value) · Risk difference (rd): 17.72 · 95% CI 7.45 to 27.98
  • Secukinumab 300 mg Every 2 Weeks (Q2W) vs Secukinumab 300 mg Every 4 Weeks (Q4W) (up to Week 16 Pre-dose) · Regression, Logistic · p = 0.0003 (One-sided p-value) · Odds ratio (or): 2.33 · 95% CI 1.44 to 3.78
SecondaryPercentage of Subjects Who Achieve Investigator Global Assessment (IGA Modified 2011) Score of 0 or 1 - Week 16 (Full Analysis Set)

IGA mod 2011 was conducted for overall psoriatic disease. The IGA modified 2011 used in this study was static, i.e., it referred exclusively to the subject's disease state at the time of the assessments, and did not attempt a comparison with any of the subject's previous disease states, whether at baseline or at a previous visit. The scale has 0 (clear) as min and 4 (severe) as max, i.e., a higher score indicates more severity.

Time frame:
16 weeks
Reported as:
Count of participants · Participants
Percentage of Subjects Who Achieve Investigator Global Assessment (IGA Modified 2011) Score of 0 or 1 - Week 16 (Full Analysis Set)
ParticipantsSecukinumab 300 mg Every 2 Weeks (Q2W)Secukinumab 300 mg Every 4 Weeks (Q4W) (up to Week 16 Pre-dose)
Percentage of Subjects Who Achieve Investigator Global Assessment (IGA Modified 2011) Score of 0 or 1 - Week 16 (Full Analysis Set)122109
Statistical analysis
  • Secukinumab 300 mg Every 2 Weeks (Q2W) vs Secukinumab 300 mg Every 4 Weeks (Q4W) (up to Week 16 Pre-dose) · Regression, Logistic · p = 0.0498 (One-sided p-value) · Risk difference (rd): 8.28 · 95% CI -1.65 to 18.20
  • Secukinumab 300 mg Every 2 Weeks (Q2W) vs Secukinumab 300 mg Every 4 Weeks (Q4W) (up to Week 16 Pre-dose) · Regression, Logistic · p = 0.0498 (One-sided p-value) · Odds ratio (or): 1.51 · 95% CI 0.92 to 2.47
SecondaryAbsolute and Relative Frequencies for Deaths, Other Serious or Clinically Significant Adverse Events or Related Discontinuations - Entire Study Period (Safety Set)

An adverse event (AE) is any untoward medical occurrence (e.g., any unfavorable and unintended sign \[including abnormal laboratory findings\], symptom or disease) in a subject or clinical investigation subject after providing written informed consent for participation in the study until the end of study visit. Therefore, an AE may or may not be temporally or causally associated with the use of a medicinal (investigational) product.

Time frame:
Adverse events were reported from first dose of study treatment until end of study treatment plus 8 weeks post treatment, up to a maximum timeframe of 470 days.
Reported as:
Count of participants · Participants
Absolute and Relative Frequencies for Deaths, Other Serious or Clinically Significant Adverse Events or Related Discontinuations - Entire Study Period (Safety Set)
ParticipantsSecukinumab 300 mg Every 2 Weeks (Q2W)Secukinumab 300 mg Every 4 Weeks (Q4W) (Safety)Secukinumab 300 mg Every 4 Weeks Non-responders Up-titration (Q4W NR up)
Patients with any AE(s)1279724
Patients with serious or other significant events - Death010
Patients with serious or other significant events - Non-fatal SAE(s)14174
Patients with serious or other significant events - Discontinued study treatment due to any AE(s)492

Adverse events

Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 8 weeks post treatment, up to a maximum timeframe of 470 days.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Secukinumab 300 mg Every 2 Weeks (Q2W)0/165 (0%)14/165 (8.5%)66/165 (40%)
Secukinumab 300 mg Every 4 Weeks (Q4W) (Safety)1/134 (0.7%)18/134 (13.4%)57/134 (42.5%)
Secukinumab 300 mg Every 4 Weeks Non-responders Up-titration (Q4W NR up)0/31 (0%)4/31 (12.9%)16/31 (51.6%)
All Patients1/330 (0.3%)36/330 (10.9%)139/330 (42.1%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventSecukinumab 300 mg Every 2 Weeks (Q2W)Secukinumab 300 mg Every 4 Weeks (Q4W) (Safety)Secukinumab 300 mg Every 4 Weeks Non-responders Up-titration (Q4W NR up)All Patients
Atrial fibrillationCardiac disorders0/1651/1341/312/330
TachycardiaCardiac disorders0/1651/1341/312/330
Inguinal herniaGastrointestinal disorders0/1650/1341/311/330
Cholecystitis chronicHepatobiliary disorders0/1650/1341/311/330
PneumoniaInfections and infestations0/1650/1341/311/330
Tooth abscessInfections and infestations0/1650/1341/311/330
FallInjury, poisoning and procedural complications1/1650/1341/312/330
SepsisInfections and infestations0/1652/1340/312/330
Non-cardiac chest painGeneral disorders2/1650/1340/312/330
Acute myocardial infarctionCardiac disorders0/1651/1340/311/330
Most frequent other events
Showing 10 of 17
Most frequent other events
EventSecukinumab 300 mg Every 2 Weeks (Q2W)Secukinumab 300 mg Every 4 Weeks (Q4W) (Safety)Secukinumab 300 mg Every 4 Weeks Non-responders Up-titration (Q4W NR up)All Patients
NasopharyngitisInfections and infestations32/16522/1345/3159/330
Upper respiratory tract infectionInfections and infestations12/1659/1343/3124/330
Neutrophil count decreasedInvestigations1/1653/1343/317/330
IntertrigoSkin and subcutaneous tissue disorders4/1650/1343/317/330
HeadacheNervous system disorders11/1656/1341/3118/330
DiarrhoeaGastrointestinal disorders10/1656/1342/3118/330
NauseaGastrointestinal disorders1/1654/1342/317/330
FatigueGeneral disorders4/1653/1342/319/330
PyrexiaGeneral disorders2/1652/1342/316/330
Tooth abscessInfections and infestations1/1650/1342/313/330

Baseline characteristics

Age, Continuous
Age, Continuous(years)Secukinumab 300 mg Every 2 Weeks (Q2W)Secukinumab 300 mg Every 4 Weeks (Q4W) (Safety)Secukinumab 300 mg Every 4 Weeks Non-responders Up-titration (Q4W NR up)Total
Mean48.2 ± 12.7346.1 ± 13.2444.7 ± 13.6147.1 ± 13.04
Sex: Female, Male
Sex: Female, Male(Participants)Secukinumab 300 mg Every 2 Weeks (Q2W)Secukinumab 300 mg Every 4 Weeks (Q4W) (Safety)Secukinumab 300 mg Every 4 Weeks Non-responders Up-titration (Q4W NR up)Total
Female39341083
Male12610121248
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Secukinumab 300 mg Every 2 Weeks (Q2W)Secukinumab 300 mg Every 4 Weeks (Q4W) (Safety)Secukinumab 300 mg Every 4 Weeks Non-responders Up-titration (Q4W NR up)Total
American Indian or Alaska Native1102
Asian4419
Native Hawaiian or Other Pacific Islander2002
Black or African American75012
White15112530306
More than one race0000
Unknown or Not Reported0000
08

Study locations

67 sites
  • Novartis Investigative Site
    Birmingham, Alabama 35205, United States
  • Novartis Investigative Site
    Phoenix, Arizona 85032, United States
  • Novartis Investigative Site
    Rogers, Arkansas 72758, United States
  • Novartis Investigative Site
    Irvine, California 92697, United States
  • Novartis Investigative Site
    Sacramento, California 95817, United States
  • Novartis Investigative Site
    Sacramento, California 95819, United States
  • Novartis Investigative Site
    San Diego, California 92123, United States
  • Novartis Investigative Site
    Santa Monica, California 90404, United States
  • Novartis Investigative Site
    Centennial, Colorado 80111, United States
  • Novartis Investigative Site
    Tampa, Florida 33612, United States
  • Novartis Investigative Site
    West Palm Beach, Florida 33409, United States
  • Novartis Investigative Site
    Alpharetta, Georgia 30022, United States
  • Novartis Investigative Site
    Snellville, Georgia 30078, United States
  • Novartis Investigative Site
    Skokie, Illinois 60077, United States
  • Novartis Investigative Site
    Indianapolis, Indiana 46256, United States
  • Novartis Investigative Site
    New Albany, Indiana 47150, United States
  • Novartis Investigative Site
    Louisville, Kentucky 40241, United States
  • Novartis Investigative Site
    Owensboro, Kentucky 42303, United States
  • Novartis Investigative Site
    Boston, Massachusetts 02111, United States
  • Novartis Investigative Site
    New Brighton, Minnesota 55112, United States
  • Novartis Investigative Site
    Saint Joseph, Missouri 64506, United States
  • Novartis Investigative Site
    East Windsor, New Jersey 08520, United States
  • Novartis Investigative Site
    Verona, New Jersey 07044, United States
  • Novartis Investigative Site
    Forest Hills, New York 11375, United States
  • Novartis Investigative Site
    New York, New York 10025 1737, United States
  • Novartis Investigative Site
    Charlotte, North Carolina 28277, United States
  • Novartis Investigative Site
    Winston-Salem, North Carolina 27157, United States
  • Novartis Investigative Site
    Fairborn, Ohio 45324, United States
  • Novartis Investigative Site
    Oregon City, Oregon 97045, United States
  • Novartis Investigative Site
    Portland, Oregon 97210, United States
  • Novartis Investigative Site
    Charleston, South Carolina 29414, United States
  • Novartis Investigative Site
    Houston, Texas 77056, United States
  • Novartis Investigative Site
    Mesquite, Texas 75150, United States
  • Novartis Investigative Site
    Pflugerville, Texas 78660, United States
  • Novartis Investigative Site
    San Antonio, Texas 78218, United States
  • Novartis Investigative Site
    Norfolk, Virginia 23507, United States
  • Novartis Investigative Site
    Wenatchee, Washington 98801, United States
  • Novartis Investigative Site
    Madison, Wisconsin 53717, United States
  • Novartis Investigative Site
    Calgary, Alberta T2G 1B1, Canada
  • Novartis Investigative Site
    Red Deer, Alberta T4N 6V7, Canada
  • Novartis Investigative Site
    Etobicoke, Ontario M8X 1Y9, Canada
  • Novartis Investigative Site
    Guelph, Ontario N1L 0B7, Canada
  • Novartis Investigative Site
    Hamilton, Ontario L8N 1V6, Canada
  • Novartis Investigative Site
    Quebec, G1V 4X7, Canada
  • Novartis Investigative Site
    Prague, Prague 1 11000, Czechia
  • Novartis Investigative Site
    Novy Jicin, 741 01, Czechia
  • Novartis Investigative Site
    Bochum, 44793, Germany
  • Novartis Investigative Site
    Frankfurt, 60590, Germany
  • Novartis Investigative Site
    Hamburg, 20246, Germany
  • Novartis Investigative Site
    Hamburg, 20537, Germany
  • Novartis Investigative Site
    Kiel, 24105, Germany
  • Novartis Investigative Site
    Leipzig, 04103, Germany
  • Novartis Investigative Site
    Debrecen, 4032, Hungary
  • Novartis Investigative Site
    Pecs, 7623, Hungary
  • Novartis Investigative Site
    Szeged, H 6725, Hungary
  • Novartis Investigative Site
    Rozzano, MI 20089, Italy
  • Novartis Investigative Site
    Modena, MO 41124, Italy
  • Novartis Investigative Site
    Perugia, PG 06100, Italy
  • Novartis Investigative Site
    Siena, SI 53100, Italy
  • Novartis Investigative Site
    Napoli, 80138, Italy
  • Novartis Investigative Site
    Chelyabinsk, 454092, Russian Federation
  • Novartis Investigative Site
    Ekaterinburg, 620023, Russian Federation
  • Novartis Investigative Site
    Kazan, 420012, Russian Federation
  • Novartis Investigative Site
    Krasnodar, 350020, Russian Federation
  • Novartis Investigative Site
    Lipetsk, 398005, Russian Federation
  • Novartis Investigative Site
    Saint Petersburg, 197022, Russian Federation
  • Novartis Investigative Site
    Saratov, 410012, Russian Federation
09

References and documents

Publications

  • Augustin M, Reich K, Yamauchi P, Pinter A, Bagel J, Dahale S, You R, Bruin G, Djimopoulos J, Paguet B, Charef P, Patekar M, Keefe D. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol. 2022 Jun;186(6):942-954. doi: 10.1111/bjd.20971. Epub 2022 Apr 8. PubMed 34981829 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com.

Data sharing details ↗ · www.clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2018 to primary completion in Sep 2019, 14 months.

Results were first posted in Jun 2021, 1 year 8 months after primary completion. A results delay was requested in Jul 2020.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 14 months is close to that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2018
First posted
Apr 20, 2018
StartActual
Jun 25, 2018
Primary completionActual
Sep 13, 2019
CompletionActual
Jul 15, 2020
Results delay requested
Jul 16, 2020
Results first posted
Jun 7, 2021
Last update
Oct 11, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 11, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03504852
Responsible party
Sponsor
First posted
Apr 20, 2018
Start date
Jun 25, 2018
Primary completion
Sep 13, 2019
Completion
Jul 15, 2020
Results posted
Jun 7, 2021
Last update
Oct 11, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Secukinumab

Start the discussion